AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Johnson & Johnson Halts Nipocalimab Trial for Rheumatoid Arthritis After Failure
ByAinvest
Friday, Aug 29, 2025 7:13 am ET1min read
Johnson & Johnson has halted studies for a potential rival to AbbVie's Humira after a mid-stage trial setback. The trial evaluated Johnson & Johnson's experimental antibody therapy, nipocalimab, for rheumatoid arthritis. The company decided to discontinue the therapy due to the failure of the trial.
Johnson & Johnson (JNJ) has decided to discontinue the development of its experimental antibody therapy, nipocalimab, for rheumatoid arthritis after a mid-stage trial failed to show significant added benefits over existing anti-tumor necrosis factor alpha (anti-TNFα) therapies. The decision follows the results of the Phase 2a DAISY proof-of-concept study, which evaluated nipocalimab in combination with anti-TNFα therapies [1].The trial, which involved patients with rheumatoid arthritis, did not demonstrate that the combination therapy provided additional benefits over anti-TNFα therapy alone. Despite the lack of new safety issues, Johnson & Johnson concluded that the drug combination did not warrant further clinical development for this indication [2].
While this setback impacts Johnson & Johnson's plans for nipocalimab in rheumatoid arthritis, the company continues to project over $5 billion in non-risk-adjusted peak-year operational sales for the drug across other conditions, including various rheumatic diseases [1].
The development of nipocalimab had been seen as a potential rival to AbbVie's (ABBV) blockbuster drug Humira, which has faced competition from U.S. biosimilars in recent years. Humira's sales potential, previously worth nearly $21 billion in 2021, has been under threat from these competitors [1].
This decision underscores the challenges pharmaceutical companies face in developing new therapies and highlights the importance of rigorous clinical trials in assessing their efficacy.
References:
[1] https://seekingalpha.com/news/4490373-jj-halts-rd-potential-rival-abbvies-humira
[2] https://www.reuters.com/business/healthcare-pharmaceuticals/jj-drops-development-combination-arthritis-drug-after-trial-setback-2025-08-28/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet